Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Capture and display of antibodies secreted by hybridoma cells enables fluorescent on-cell screening.

Puligedda RD, Sharma R, Al-Saleem FH, Kouiavskaia D, Velu AB, Kattala CD, Prendergast GC, Lynch DR, Chumakov K, Dessain SK.

MAbs. 2019 Apr;11(3):546-558. doi: 10.1080/19420862.2019.1574520. Epub 2019 Feb 22.

2.

Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis.

Viktorova EG, Khattar SK, Kouiavskaia D, Laassri M, Zagorodnyaya T, Dragunsky E, Samal S, Chumakov K, Belov GA.

J Virol. 2018 Aug 16;92(17). pii: e00976-18. doi: 10.1128/JVI.00976-18. Print 2018 Sep 1.

3.

Assessing the potency and immunogenicity of inactivated poliovirus vaccine after exposure to freezing temperatures.

White JA, Estrada M, Weldon WC, Chumakov K, Kouiavskaia D, Fournier-Caruana J, Stevens E, Gary HE Jr, Maes EF, Oberste MS, Snider CJ, Anand A, Chen D.

Biologicals. 2018 May;53:30-38. doi: 10.1016/j.biologicals.2018.03.002. Epub 2018 Mar 14.

4.

Pathogenic Events in a Nonhuman Primate Model of Oral Poliovirus Infection Leading to Paralytic Poliomyelitis.

Shen L, Chen CY, Huang D, Wang R, Zhang M, Qian L, Zhu Y, Zhang AZ, Yang E, Qaqish A, Chumakov K, Kouiavskaia D, Vignuzzi M, Nathanson N, Macadam AJ, Andino R, Kew O, Xu J, Chen ZW.

J Virol. 2017 Jun 26;91(14). pii: e02310-16. doi: 10.1128/JVI.02310-16. Print 2017 Jul 15.

5.

Characterization of human monoclonal antibodies that neutralize multiple poliovirus serotypes.

Puligedda RD, Kouiavskaia D, Al-Saleem FH, Kattala CD, Nabi U, Yaqoob H, Bhagavathula VS, Sharma R, Chumakov K, Dessain SK.

Vaccine. 2017 Oct 4;35(41):5455-5462. doi: 10.1016/j.vaccine.2017.03.038. Epub 2017 Mar 24.

PMID:
28343771
6.

Fluorescence Adherence Inhibition Assay: A Novel Functional Assessment of Blocking Virus Attachment by Vaccine-Induced Antibodies.

Asati A, Kachurina O, Karol A, Dhir V, Nguyen M, Parkhill R, Kouiavskaia D, Chumakov K, Warren W, Kachurin A.

PLoS One. 2016 Feb 10;11(2):e0144261. doi: 10.1371/journal.pone.0144261. eCollection 2016.

7.

A single chimpanzee-human neutralizing monoclonal antibody provides post-exposure protection against type 1 and type 2 polioviruses.

Kouiavskaia D, Chen Z, Dragunsky E, Mirochnitchenko O, Purcell R, Chumakov K.

J Clin Virol. 2015 Apr;65:32-7. doi: 10.1016/j.jcv.2015.01.023. Epub 2015 Feb 3.

8.

Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV-Infected Adults.

Troy SB, Kouiavskaia D, Siik J, Kochba E, Beydoun H, Mirochnitchenko O, Levin Y, Khardori N, Chumakov K, Maldonado Y.

J Infect Dis. 2015 Jun 15;211(12):1969-76. doi: 10.1093/infdis/jiu841. Epub 2015 Jan 7.

9.

Intradermal inactivated poliovirus vaccine: a preclinical dose-finding study.

Kouiavskaia D, Mirochnitchenko O, Dragunsky E, Kochba E, Levin Y, Troy S, Chumakov K.

J Infect Dis. 2015 May 1;211(9):1447-50. doi: 10.1093/infdis/jiu624. Epub 2014 Nov 12.

10.

Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer.

Klyushnenkova EN, Riabov VB, Kouiavskaia DV, Wietsma A, Zhan M, Alexander RB.

Prostate. 2014 Oct;74(14):1423-32. doi: 10.1002/pros.22858. Epub 2014 Aug 11.

PMID:
25111463
11.

New small-molecule inhibitors effectively blocking picornavirus replication.

Ford Siltz LA, Viktorova EG, Zhang B, Kouiavskaia D, Dragunsky E, Chumakov K, Isaacs L, Belov GA.

J Virol. 2014 Oct;88(19):11091-107. doi: 10.1128/JVI.01877-14. Epub 2014 Jul 9.

12.

Human monoclonal antibodies that neutralize vaccine and wild-type poliovirus strains.

Puligedda RD, Kouiavskaia D, Adekar SP, Sharma R, Devi Kattala C, Rezapkin G, Bidzhieva B, Dessain SK, Chumakov K.

Antiviral Res. 2014 Aug;108:36-43. doi: 10.1016/j.antiviral.2014.05.005. Epub 2014 May 10.

PMID:
24824031
13.

Cross-neutralizing human anti-poliovirus antibodies bind the recognition site for cellular receptor.

Chen Z, Fischer ER, Kouiavskaia D, Hansen BT, Ludtke SJ, Bidzhieva B, Makiya M, Agulto L, Purcell RH, Chumakov K.

Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20242-7. doi: 10.1073/pnas.1320041110. Epub 2013 Nov 25.

14.

Vaccine poliovirus shedding and immune response to oral polio vaccine in HIV-infected and -uninfected Zimbabwean infants.

Troy SB, Musingwini G, Halpern MS, Huang C, Stranix-Chibanda L, Kouiavskaia D, Shetty AK, Chumakov K, Nathoo K, Maldonado YA.

J Infect Dis. 2013 Aug 15;208(4):672-8. doi: 10.1093/infdis/jit208. Epub 2013 May 9.

15.

A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer.

Klyushnenkova EN, Kouiavskaia DV, Parkins CJ, Caposio P, Botto S, Alexander RB, Jarvis MA.

J Immunother. 2012 Jun;35(5):390-9. doi: 10.1097/CJI.0b013e3182585d50.

16.

Immunologic response to oral polio vaccine in human immunodeficiency virus-infected and uninfected Zimbabwean children.

Gnanashanmugam D, Troy SB, Musingwini G, Huang C, Halpern MS, Stranix-Chibanda L, Shetty AK, Kouiavskaia D, Nathoo K, Chumakov K, Maldonado YA.

Pediatr Infect Dis J. 2012 Feb;31(2):176-80. doi: 10.1097/INF.0b013e31823faa5f.

PMID:
22146742
17.

Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073.

Kouiavskaia DV, Dragunsky EM, Liu HM, Oberste MS, Collett MS, Chumakov KM.

Antivir Ther. 2011;16(7):999-1004. doi: 10.3851/IMP1838.

PMID:
22024515
18.

Immunogenicity of inactivated polio vaccine with concurrent antiviral V-073 administration in mice.

Kouiavskaia D, Collett MS, Dragunsky EM, Sarafanov A, Chumakov KM.

Clin Vaccine Immunol. 2011 Aug;18(8):1387-90. doi: 10.1128/CVI.05147-11. Epub 2011 Jun 29.

19.

Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis.

Chen Z, Chumakov K, Dragunsky E, Kouiavskaia D, Makiya M, Neverov A, Rezapkin G, Sebrell A, Purcell R.

J Virol. 2011 May;85(9):4354-62. doi: 10.1128/JVI.02553-10. Epub 2011 Feb 23.

20.

Repertoire of antibodies against type 1 poliovirus in human sera.

Rezapkin G, Neverov A, Cherkasova E, Vidor E, Sarafanov A, Kouiavskaia D, Dragunsky E, Chumakov K.

J Virol Methods. 2010 Nov;169(2):322-31. doi: 10.1016/j.jviromet.2010.07.037. Epub 2010 Aug 4.

PMID:
20691212
21.

T-cell recognition of prostatic peptides in men with chronic prostatitis/chronic pelvic pain syndrome.

Kouiavskaia DV, Southwood S, Berard CA, Klyushnenkova EN, Alexander RB.

J Urol. 2009 Nov;182(5):2483-9. doi: 10.1016/j.juro.2009.07.067. Epub 2009 Sep 17.

23.
24.

The binding sites for the very low density lipoprotein receptor and low-density lipoprotein receptor-related protein are shared within coagulation factor VIII.

Ananyeva NM, Makogonenko YM, Kouiavskaia DV, Ruiz J, Limburg V, Meijer AB, Khrenov AV, Shima M, Strickland DK, Saenko EL.

Blood Coagul Fibrinolysis. 2008 Mar;19(2):166-77. doi: 10.1097/MBC.0b013e3282f5457b.

PMID:
18277139
25.

Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic acid phosphatase.

Klyushnenkova EN, Kouiavskaia DV, Kodak JA, Vandenbark AA, Alexander RB.

Prostate. 2007 Jul 1;67(10):1019-28.

PMID:
17455230
26.

The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor.

Ruiz J, Kouiavskaia D, Migliorini M, Robinson S, Saenko EL, Gorlatova N, Li D, Lawrence D, Hyman BT, Weisgraber KH, Strickland DK.

J Lipid Res. 2005 Aug;46(8):1721-31. Epub 2005 May 1.

27.

Molecular defects in coagulation Factor VIII and their impact on Factor VIII function.

Saenko EL, Ananyeva N, Kouiavskaia D, Schwinn H, Josic D, Shima M, Hauser CA, Pipe S.

Vox Sang. 2002 Aug;83(2):89-96. Review.

28.

Intrinsic pathway of blood coagulation contributes to thrombogenicity of atherosclerotic plaque.

Ananyeva NM, Kouiavskaia DV, Shima M, Saenko EL.

Blood. 2002 Jun 15;99(12):4475-85.

29.

Haemophilia A: effects of inhibitory antibodies on factor VIII functional interactions and approaches to prevent their action.

Saenko EL, Ananyeva NM, Kouiavskaia DV, Khrenov AV, Anderson JA, Shima M, Qian J, Scott D.

Haemophilia. 2002 Jan;8(1):1-11. Review.

PMID:
11886458
30.

Development and applications of surface plasmon resonance-based von Willebrand factor-collagen binding assay.

Saenko E, Kannicht C, Loster K, Sarafanov A, Khrenov A, Kouiavskaia D, Shima M, Ananyeva N, Schwinn H, Gruber G, Josic D.

Anal Biochem. 2002 Mar 15;302(2):252-62.

PMID:
11878805
31.

Molecular basis for different ability of low-density and high-density lipoproteins to support activity of the intrinsic Xase complex.

Khrenov A, Sarafanov A, Ananyeva N, Kouiavskaia D, Shima M, Schwinn H, Josic D, Saenko E.

Thromb Res. 2002 Jan 1;105(1):87-93. No abstract available.

PMID:
11864712
32.

Catabolism of the coagulation factor VIII: can we prolong lifetime of f VIII in circulation?

Ananyeva NM, Kouiavskaia DV, Shima M, Saenko EL.

Trends Cardiovasc Med. 2001 Aug;11(6):251-7. Review.

PMID:
11673057

Supplemental Content

Loading ...
Support Center